[Summary of Current Report on Form 8-K (July 1, 2025)](index=1&type=section&id=Form%208-K%20Current%20Report) [Completion of Acquisition (Item 2.01)](index=2&type=section&id=Item%202.01%20Completion%20of%20Acquisition%20or%20Disposition%20of%20Assets) Astrana Health completed the acquisition of Alta Newport Hospital and Prospect Health Plan for **$707.9 million**, financed by a term loan, and established ancillary agreements - On July 1, 2025, the Company completed the acquisition of all outstanding equity interests of Alta Newport Hospital, LLC (d/b/a Foothill Regional Medical Center) and Prospect Health Plan, Inc., and substantially all assets of certain subsidiaries of PHP Holdings, LLC ("PHPH")[5](index=5&type=chunk) - A letter agreement was executed to reduce the aggregate purchase price and remove certain post-closing adjustments; additionally, a transition services agreement was established for the sellers to provide post-closing services to the Company[6](index=6&type=chunk) Purchase Price Details | Detail | Amount/Description | | :--- | :--- | | Original Purchase Price | $745.0 million | | Final Adjusted Purchase Price | $707.9 million | | Financing Source | Five-year delayed draw term loan | | Amount Drawn for Transaction | $707.9 million | [Financial Guidance Update (Item 2.02)](index=3&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) The company reaffirmed Q2 guidance and updated full-year 2025 revenue and adjusted EBITDA forecasts, noting their preliminary and unaudited nature - The Company issued a press release on July 2, 2025, which reaffirmed its second-quarter guidance and updated its full-year 2025 revenue and adjusted EBITDA guidance[10](index=10&type=chunk) - The preliminary financial results and forecasts are based on currently available information, are inherently uncertain, and have not been audited; the company has no obligation to update these forecasts[11](index=11&type=chunk) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) The report includes forward-looking statements regarding financial guidance and acquisition effects, subject to risks like business disruption and debt servicing challenges - The report contains forward-looking statements identified by words such as "forecast," "guidance," "projects," and "estimates"[15](index=15&type=chunk) - Key risks include diversion of management's attention, increased costs related to the transaction, business disruption, potential difficulties in employee retention, ability to pay principal and interest on debt, and the ability to realize the intended benefits of the transaction[15](index=15&type=chunk) [Financial Statements and Exhibits (Item 9.01)](index=4&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) Required financial statements and pro forma information for acquired businesses will be filed via amendment within 71 days, with key agreements incorporated by reference - The required financial statements of the acquired businesses and pro forma financial information will be filed by amendment to this Current Report no later than 71 days after the report's required filing date[16](index=16&type=chunk) Exhibit Details | Exhibit No. | Description | | :--- | :--- | | 2.1 | Asset and Equity Purchase Agreement, dated November 8, 2024 | | 10.1 | Second Amended and Restated Credit Agreement, dated February 26, 2025 | | 99.1 | Press Release dated July 2, 2025 |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdiction (I ...

Exhibit 99.1 Astrana Health, Inc. Reports First Quarter 2025 Results Company to Host Conference Call on Thursday, May 8, 2025, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., May 8, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated fin ...

Financial Highlights for Year Ended December 31, 2024: All comparisons are to the year ended December 31, 2023 unless otherwise stated. See "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin" and "Use of Non-GAAP Financial Measures" below for additional information. Exhibit 99.1 Astrana Health, Inc. Reports Fourth Quarter and Year-End 2024 Results Company to Host Conference Call on Thursday, February 27, 2025, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., February 27, 2025 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdictio ...

Exhibit 99.1 Astrana Health, Inc. Reports Third Quarter 2024 Results Company to Host Conference Call on Thursday, November 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., November 7, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consol ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdiction (I. ...

Exhibit 99.1 +. Astrana Health Astrana Health, Inc. Reports Second Quarter 2024 Results Company to Host Conference Call on Wednesday, August 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., August 7, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today anno ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, $0.001 par value per share ASTH The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commis ...

Exhibit 99.1 Astrana Health, Inc. Reports First Quarter 2024 Results Company to Host Conference Call on Tuesday, May 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., May 7, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated fina ...